HAWKINS INC. - 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2009 (the third quarter of fiscal 2010) and the nine months ended December 31, 2009. Hawkins, Inc. is a distributor of bulk and specialty chemicals operating primarily in the United States through two reportable segments: Industrial and Water Treatment. The company discontinued its Pharmaceutical segment in May 2009, with results reported as discontinued operations.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 31, 2009 | 9 Months Ended Dec 31, 2009 |
|---|---|---|
| Sales | $60,627 | $199,189 |
| Gross Profit | $15,855 (26.2% margin) | $49,127 (24.7% margin) |
| Operating Income | $9,408 (15.5% margin) | $29,757 (14.9% margin) |
| Net Income | $5,595 | $18,313 |
| Diluted EPS | $0.54 | $1.78 |
| Cash from Operations | N/A | $29,666 |
| Cash & Equivalents (Ending) | $12,854 | $12,854 |
| Total Investments (Available-for-Sale) | $33,340 | $33,340 |
| Debt | None reported | None reported |
Note: The company reported no long-term debt or current debt obligations in the balance sheet liabilities section.
Material Changes vs. Prior Period
- Sales Decline: Sales decreased 19.8% ($14.9M) in the quarter and 8.0% ($17.4M) for the nine months compared to the prior year. This was driven by lower selling prices for bulk chemicals (e.g., caustic soda) reflecting lower commodity costs and reduced demand.
- Margin Expansion: Despite lower sales, gross profit margins improved (26.2% vs. 24.0% in the quarter). This was significantly aided by a LIFO reserve decrease of $2.1M for the quarter and $9.1M for the nine months due to falling raw material costs.
- Segment Performance:
- Industrial: Sales dropped 24.7% in the quarter due to lower commodity prices and volumes. Operating income fell $2.8M.
- Water Treatment: Sales were relatively flat (-5.3% in quarter, +0.5% for nine months). Operating income increased $1.0M in the quarter and $4.4M for the nine months, driven by higher-margin specialty products.
- Cash Flow: Operating cash flow surged to $29.7M for the nine months (vs. $5.5M prior year) due to significant reductions in working capital (inventory and receivables) driven by lower commodity prices.
Outlook, Risks, and Management Commentary
- Raw Material Volatility: Management notes that raw material costs have stabilized at levels significantly below the peaks of late fiscal 2009. The company uses LIFO accounting, which causes reported gross profit to fluctuate with commodity price changes.
- Capital Expenditures: The company invested in two new facilities (Centralia, IL and Minneapolis, MN) with total costs of approximately $10M. Capital expenditures for the nine months were $6.6M, down from $10.2M in the prior year due to timing.
- Liquidity: The company maintains a strong liquidity position with $46.2M in cash and investments. No debt is outstanding. Management expects operating cash flows to be sufficient to fund future capital expenditures.
- Risks: Primary risks include the cyclical nature of commodity chemical prices and the inability to pass cost increases to customers. The company does not currently hedge commodity purchases.
- Discontinued Operations: The Pharmaceutical segment was sold in May 2009. Future payments based on gross profit of the sold business may be recorded as gains.
Investor Verification Checklist
- LIFO Impact: Verify the sustainability of gross margins given the significant one-time benefit from the LIFO reserve reduction ($9.1M for nine months) caused by falling commodity prices.
- Volume vs. Price: Distinguish between sales declines caused by lower pricing (passing on lower costs) versus actual volume declines in the Industrial segment.
- Working Capital Normalization: Assess if the massive improvement in operating cash flow ($29.7M) is a recurring trend or a one-time benefit from destocking inventory due to price drops.
- Capital Project ROI: Monitor the performance of the new Centralia and Minneapolis facilities to ensure they generate expected returns on the $10M investment.
- Discontinued Operations: Track any future contingent payments received from the sale of the Pharmaceutical segment.